Sabby Management, LLC Genprex, Inc. Transaction History

Sabby Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$2.9 - $4.29 $343,893 - $508,725	-118,584 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.99 - $3.64 $235,982 - $431,645	118,584 New	118,584 $372,000
Q1 2020 May 15, 2020	SELL	$0.28 - $6.23 $124,163 - $2.76 Million	-443,441 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$0.24 - $0.75 $32,131 - $100,411	-133,882 Reduced 23.19%	443,441 $142,000
Q3 2019 Nov 15, 2019	SELL	$0.8 - $1.18 $52,777 - $77,846	-65,972 Reduced 10.26%	577,323 $462,000
Q2 2019 Aug 14, 2019	BUY	$1.2 - $1.85 $69,266 - $106,785	57,722 Added 9.86%	643,295 $798,000
Q1 2019 May 15, 2019	SELL	$1.28 - $2.15 $315,738 - $530,342	-246,671 Reduced 29.64%	585,573 $911,000
Q4 2018 Feb 14, 2019	BUY	$1.0 - $2.15 $99,044 - $212,944	99,044 Added 13.51%	832,244 $915,000
Q3 2018 Nov 14, 2018	BUY	$2.2 - $8.08 $701,690 - $2.58 Million	318,950 Added 76.99%	733,200 $1.66 Million
Q2 2018 Aug 14, 2018	BUY	$3.84 - $15.9 $1.59 Million - $6.59 Million	414,250 New	414,250 $3.17 Million

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $112M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.